Icariin attenuates vascular endothelial dysfunction by inhibiting inflammation through GPER/Sirt1/HMGB1 signaling pathway in type 1 diabetic rats

Abstract

Icariin, a flavonoid glycoside, is extracted from Epimedium. This study aimed to investigate the vascular protective effects of icariin in type 1 diabetic rats by inhibiting high-mobility group box 1 (HMGB1)-related inflammation and exploring its potential mechanisms. The impact of icariin on vascular dysfunction was assessed in streptozotocin (STZ)-induced diabetic rats through vascular reactivity studies. Western blotting and immunofluorescence assays were performed to measure the expressions of target proteins. The release of HMGB1 and pro-inflammation cytokines were measured by enzyme-linked immunosorbent assay (ELISA). The results revealed that icariin administration enhanced acetylcholine-induced vasodilation in the aortas of diabetic rats. It also notably reduced the release of pro-inflammatory cytokines, including interleukin-8 (IL-8), IL-6, IL-1β, and tumor necrosis factor-alpha (TNF-α) in diabetic rats and high glucose (HG)-induced human umbilical vein endothelial cells (HUVECs). The results also unveiled that the pro-inflammatory cytokines in the culture medium of HUVECs could be increased by rHMGB1. The increased release of HMGB1 and upregulated expressions of HMGB1-related inflammatory factors, including advanced glycation end products (RAGE), Toll-like receptor 4 (TLR4), and phosphorylated p65 (p-p65) in diabetic rats and HG-induced HUVECs, were remarkably suppressed by icariin. Notably, HMGB1 translocation from the nucleus to the cytoplasm in HUVECs under HG was inhibited by icariin. Meanwhile, icariin could activate G protein-coupled estrogen receptor (GPER) and sirt1. To explore the role of GPER and Sirt1 in the inhibitory effect of icariin on HMGB1 release and HMGB-induced inflammation, GPER inhibitor and Sirt1 inhibitor were used in this study. These inhibitors diminished the effects of icariin on HMGB1 release and HMGB1-induced inflammation. Specifically, the GPER inhibitor also negated the activation of Sirt1 by icariin. These findings suggest that icariin activates GPER and increases the expression of Sirt1, which in turn reduces HMGB1 translocation and release, thereby improving vascular endothelial function in type 1 diabetic rats by inhibiting inflammation.

Keywords

Icariin / Diabetes / Inflammation / Vascular endothelial dysfunction / GPER / HMGB1

References

[1] Rosengren A, Dikaiou P. Cardiovascular outcomes in type 1 and type 2 diabetes[J]. Diabetologia, 2023, 66(3): 425-437.

[2] Hu Y, Chen M, Wang M, et al. Flow-mediated vasodilation through mechanosensitive G protein-coupled receptors in endothelial cells[J]. Trends Cardiovasc Med, 2022, 32(2): 61-70.

[3] Yao Y, Song Q, Hu C, et al. Endothelial cell metabolic memory causes cardiovascular dysfunction in diabetes[J]. Cardiovasc Res, 2022, 118(1): 196-211.

[4] Maruhashi T, Higashi Y. Pathophysiological sssociation between diabetes mellitus and endothelial dysfunction[J]. Antioxidants (Basel), 2021, 10(8): 1306.

[5] Stark K, Massberg S. Interplay between inflammation and thrombosis in cardiovascular pathology[J]. Nat Rev Cardiol, 2021, 18(9): 666-682.

[6] Antonopoulos AS, Angelopoulos A, Papanikolaou P, et al. Biomarkers of vascular inflammation for cardiovascular risk prognostication: a meta-analysis[J]. JACC Cardiovasc Imaging, 2022, 15(3): 460-471.

[7] Othman ZA, Zakaria Z, Suleiman JB, et al. Bee bread ameliorates vascular inflammation and impaired vasorelaxation in obesity-induced vascular damage rat model: the role of eNOS/NO/cGMP-signaling pathway[J]. Int J Mol Sci, 2021, 22(8): 4225.

[8] De La PEñA JB, Barragan-Iglesias P, Lou TF, et al. Intercellular arc signaling regulates vasodilation[J]. J Neurosci, 2021, 41(37): 7712-7726.

[9] Rohm TV, Meier DT, Olefsky JM, et al. Inflammation in obesity, diabetes, and related disorders[J]. Immunity, 2022, 55(1): 31-55.

[10] Wang S, Zhang Y. HMGB1 in inflammation and cancer[J]. J Hematol Oncol, 2020, 13(1): 116.

[11] Nogueira-Machado JA, Volpe CM, Veloso CA, et al. HMGB1, TLR and RAGE: a functional tripod that leads to diabetic inflammation[J]. Expert Opin Ther Targets, 2011, 15(8): 1023-1035.

[12] Giovannini S, Tinelli G, Biscetti F, et al. Serum high mobility group box-1 and osteoprotegerin levels are associated with peripheral arterial disease and critical limb ischemia in type 2 diabetic subjects[J]. Cardiovasc Diabetol, 2017, 16(1): 99.

[13] Wang C, Jiang J, Zhang X, et al. Inhibiting HMGB1 reduces cerebral ischemia reperfusion injury in diabetic mice[J]. Inflammation, 2016, 39(6): 1862-1870.

[14] Xie W, Zhu T, Dong X, et al. HMGB1-triggered inflammation inhibition of notoginseng leaf triterpenes against cerebral ischemia and reperfusion injury via MAPK and NF-κB signaling pathways[J]. Biomolecules, 2019, 9(10): 512.

[15] Liao J, Xie S S, Deng Y, et al. PRDX6-mediated pulmonary artery endothelial cell ferroptosis contributes to monocrotaline-induced pulmonary hypertension[J]. Microvasc Res, 2023, 146: 104471.

[16] Belmadani S, Matrougui K. Role of high mobility group box 1 in cardiovascular diseases[J]. Inflammation, 2022, 45(5): 1864-1874.

[17] Ahn JG, Bae Y, Shin D, et al. HMGB1 gene polymorphism is associated with coronary artery lesions and intravenous immunoglobulin resistance in Kawasaki disease[J]. Rheumatology (Oxford), 2019, 58(5): 770-775.

[18] Zhu Z, Peng X, Li X, et al. HMGB1 impairs endothelium-dependent relaxation in diabetes through TLR4/eNOS pathway[J]. FASEB J, 2020, 34(6): 8641-8652.

[19] Shen Y, Cao H, Chen F, et al. A cross-sectional study of vitreous and serum high mobility group box-1 levels in proliferative diabetic retinopathy[J]. Acta Ophthalmol, 2020, 98(2): e212-e216.

[20] He C, Wang Z, Shi J. Pharmacological effects of icariin[J]. Adv Pharmacol, 2020, 87: 179-203.

[21] Hu Y, Sun B, Liu K, et al. Icariin attenuates high-cholesterol diet induced atherosclerosis in rats by inhibition of inflammatory response and p38 MAPK signaling pathway[J]. Inflammation, 2016, 39(1): 228-236.

[22] Dai M, Chen B, Wang X, et al. Icariin enhance mild hypothermia-induced neuroprotection via inhibiting the activation of NF-κB in experimental ischemic stroke[J]. Metab Brain Dis, 2021, 36(7): 1779-1790.

[23] Yao W, Wang K, Wang X, et al. Icariin ameliorates endothelial dysfunction in type 1 diabetic rats by suppressing ER stress via the PPARα/Sirt1/AMPKα pathway[J]. J Cell Physiol, 2021, 236(3): 1889-1902.

[24] Liu L, Zhao Z, Lu L, et al. Icariin and icaritin ameliorated hippocampus neuroinflammation via inhibiting HMGB1-related pro-inflammatory signals in lipopolysaccharide-induced inflammation model in C57BL/6 J mice[J]. Int Immunopharmacol, 2019, 68: 95-105.

[25] Liu J, Liu J, Tong X, et al. Network pharmacology prediction and molecular docking-based strategy to discover the potential pharmacological mechanism of Huai Hua San against ulcerative colitis[J]. Drug Des Devel Ther, 2021, 15: 3255-3276.

[26] Barbu E, Popescu MR, Popescu AC, et al. Inflammation as a precursor of atherothrombosis, diabetes and early vascular aging[J]. Int J Mol Sci, 2022, 23(2): 963.

[27] Yang H, Wang H, Andersson U. Targeting inflammation driven by HMGB1[J]. Front Immunol, 2020, 11: 484.

[28] Behl T, Sharma E, Sehgal A, et al. Expatiating the molecular approaches of HMGB1 in diabetes mellitus: highlighting signalling pathways via RAGE and TLRs[J]. Mol Biol Rep, 2021, 48(2): 1869-1881.

[29] Rabadi MM, Xavier S, Vasko R, et al. High-mobility group box 1 is a novel deacetylation target of Sirtuin1[J]. Kidney Int, 2015, 87(1): 95-108.

[30] Qiao C, Ye W, Li S, et al. Icariin modulates mitochondrial function and apoptosis in high glucose-induced glomerular podocytes through G protein-coupled estrogen receptors[J]. Mol Cell Endocrinol, 2018, 473: 146-155.

[31] Santolla MF, Avion S, Pellegrino M, et al. SIRT1 is involved in oncogenic signaling mediated by GPER in breast cancer[J]. Cell Death Dis, 2015, 6(7): e1834.

[32] Juguilon C, Wang Z, Wang Y, et al. Mechanism of the switch from NO to H₂O₂ in endothelium-dependent vasodilation in diabetes[J]. Basic Res Cardiol, 2022, 117(1): 2.

[33] He A, Guo Y, Xu Z, et al. Hypoglycaemia aggravates impaired endothelial-dependent vasodilation in diabetes by suppressing endothelial nitric oxide synthase activity and stimulating inducible nitric oxide synthase expression[J]. Microvasc Res, 2023, 146: 104468.

[34] Xu HB, Hhuang ZQ. Vasorelaxant effects of icariin on isolated canine coronary artery[J]. J Cardiovasc Pharmacol, 2007, 49(4): 207-213.

[35] Wang L, Cheng CK, Yi M, et al. Targeting endothelial dysfunction and inflammation[J]. J Mol Cell Cardiol, 2022, 168: 58-67.

[36] Qiao C, Wang H, Song Z, et al. Icariin attenuates diabetic cardiomyopathy and downregulates extracellular matrix proteins in heart tissue of type 2 diabetic rats[J]. Pharmacology, 2020, 105

[37] ( Qiao C, Wang H, Song Z, et al. Icariin attenuates diabetic cardiomyopathy and downregulates extracellular matrix proteins in heart tissue of type 2 diabetic rats[J]. Pharmacology, 2020, 105(9-10): 576-585.

[38] Singh WR, Sharma A, Devi HS, et al. Icariin improves cutaneous wound healing in streptozotocin-induced diabetic rats[J]. J Tissue Viability, 2022, 31(1): 197-206.

[39] Yang K, Cao F, Wang W, et al. The relationship between HMGB1 and autophagy in the pathogenesis of diabetes and its complications[J]. Front Endocrinol (Lausanne), 2023, 14: 1141516.

[40] Liu Y, Chen L, Gao L, et al. LRRK2 deficiency protects the heart against myocardial infarction injury in mice via the P53/HMGB1 pathway[J]. Free Radic Biol Med, 2022, 191: 119-127.

[41] Deng C, Zhao L, Yang Z, et al. Targeting HMGB1 for the treatment of sepsis and sepsis-induced organ injury[J]. Acta Pharmacol Sin, 2022, 43(3): 520-528.

[42] Zhan Y, Ling Y, Deng Q, et al. HMGB1-mediated neutrophil extracellular trap formation exacerbates intestinal ischemia/reperfusion-induced acute lung injury[J]. J Immunol, 2022, 208(4): 968-78.

[43] Rudjito R, Agalave NM, Farinotti B, et al. Sex- and cell-dependent contribution of peripheral high mobility group box 1 and TLR4 in arthritis-induced pain[J]. Pain, 2021, 162(2): 459-470.

[44] Ikram FZ, Arulsamy A, Retinasamy T, et al. The role of high mobility group box 1 (HMGB1) in neurodegeneration: a systematic review[J]. Curr Neuropharmacol, 2022, 20(11): 2221-2245.

[45] Piva S, Albani F, Fagoni N, et al. High-mobility group box-1 protein as a novel biomarker to diagnose healthcare-associated ventriculitis and meningitis: a pilot study[J]. Minerva Anestesiol, 2021, 87(1): 43-51.

[46] Wang JD, Wang YY, Lin SY, et al. Exosomal HMGB1 promoted cancer malignancy[J]. Cancers, 2021, 13(4): 877.

[47] Arterburn JB, Prossnitz ER. G protein-coupled estrogen receptor GPER: molecular pharmacology and therapeutic applications[J]. Annu Rev Pharmacol Toxicol, 2023, 63: 295-320.

[48] Barton M, Prossnitz ER. Emerging roles of GPER in diabetes and atherosclerosis[J]. Trends Endocrinol Metab, 2015, 26(4): 185-192.

[49] Aryan L, Younessi D, Zargari M, et al. The role of estrogen receptors in cardiovascular disease[J]. Int J Mol Sci, 2020, 21(12): 4314.

[50] Feidman RD, Limbird LE. GPER (GPR30): a nongenomic receptor (GPCR) for steroid hormones with implications for cardiovascular disease and cancer[J]. Annu Rev Pharmacol Toxicol, 2017, 57: 567-584.

[51] Li YC, Ding XS, Li HM, et al. Icariin attenuates high glucose-induced type IV collagen and fibronectin accumulation in glomerular mesangial cells by inhibiting transforming growth factor-β production and signalling through G protein-coupled oestrogen receptor 1[J]. Clin Exp Pharmacol Physiol, 2013, 40(9): 635-643.

[52] Li Z, Cheng L, Liang H, et al. GPER inhibits diabetes-mediated RhoA activation to prevent vascular endothelial dysfunction[J]. Eur J Cell Biol, 2016, 95(2): 100-113.

[53] Liu L, Liu S, Luo H, et al. GPR30-mediated HMGB1 upregulation in CAFs induces autophagy and tamoxifen resistance in ERα-positive breast cancer cells[J]. Aging, 2021, 13(12): 16178-16197.

[54] Chen R, Kang R, Tang D. The mechanism of HMGB1 secretion and release[J]. Exp Mol Med, 2022, 54(2): 91-102.

[55] Shin J, Kim YH, Lee B, et al. USP13 regulates HMGB1 stability and secretion through its deubiquitinase activity[J]. Mol Med, 2022, 28(1): 164.

[56] Gui YL, Zhang J, Chen L, et al. Icariin, a flavonoid with anti-cancer effects, alleviated paclitaxel-induced neuropathic pain in a SIRT1-dependent manner[J]. Mol Pain, 2018, 14: 1744806918768970.

[57] Wei W, Guo X, Gu L, et al. Bone marrow mesenchymal stem cell exosomes suppress phosphate-induced aortic calcification via SIRT6-HMGB1 deacetylation[J]. Stem Cell Res Ther, 2021, 12(1): 235.

[58] Kong Q, Li Y, Liang Q, et al. SIRT6-PARP1 is involved in HMGB1 polyADP-ribosylation and acetylation and promotes chemotherapy-induced autophagy in leukemia[J]. Cancer Biol Ther, 2020, 21(4): 320-331.

[59] Li L, Chen B, Aa T, et al. BaZiBuShen alleviates altered testicular morphology and spermatogenesis and modulates Sirt6/P53 and Sirt6/NF-κB pathways in aging mice induced by D-galactose and NaNO₂[J]. J Ethnopharmacol, 2021, 271: 113810.

Funding

National New Drug Innovation Program of China(2017ZX09301004)

National Natural Science Foundation of China(81873131)